Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Improving the design of studies evaluating the impact of diagnostic tests for tuberculosis on health outcomes: a qualitative study of perspectives of diverse stakeholders.

Ochodo EA, Naidoo S, Schumacher S, Steingart K, Deeks J, Cobelens F, Bossuyt PM, Young T, Nicol MP.

Wellcome Open Res. 2019 Nov 21;4:183. doi: 10.12688/wellcomeopenres.15551.1. eCollection 2019.

2.

Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.

Phommasone K, van Leth F, Peto TJ, Landier J, Nguyen TN, Tripura R, Pongvongsa T, Lwin KM, Kajeechiwa L, Thwin MM, Parker DM, Wiladphaingern J, Nosten S, Proux S, Nguon C, Davoeung C, Rekol H, Adhikari B, Promnarate C, Chotivanich K, Hanboonkunupakarn B, Jittmala P, Cheah PY, Dhorda M, Imwong M, Mukaka M, Peerawaranun P, Pukrittayakamee S, Newton PN, Thwaites GE, Day NPJ, Mayxay M, Hien TT, Nosten FH, Cobelens F, Dondorp AM, White NJ, von Seidlein L.

PLoS One. 2020 Feb 5;15(2):e0228190. doi: 10.1371/journal.pone.0228190. eCollection 2020.

3.

Correction to: The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.

Phommasone K, van Leth F, Imwong M, Henriques G, Pongvongsa T, Adhikari B, Peto TJ, Promnarate C, Dhorda M, Sirithiranont P, Mukaka M, Peerawaranun P, Day NPJ, Cobelens F, Dondorp AM, Newton PN, White NJ, von Seidlein L, Mayxay M.

Malar J. 2020 Jan 21;19(1):32. doi: 10.1186/s12936-020-3124-0.

4.

Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations.

Esmail H, Cobelens F, Goletti D.

Eur Respir J. 2020 Mar 5;55(3). pii: 1901957. doi: 10.1183/13993003.01957-2019. Print 2020 Mar. No abstract available.

5.

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Xia H, van den Hof S, Cobelens F, Zhou Y, Zhao B, Wang S, Zhao Y.

BMC Infect Dis. 2020 Jan 7;20(1):19. doi: 10.1186/s12879-020-4758-9.

6.

The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.

Phommasone K, van Leth F, Imwong M, Henriques G, Pongvongsa T, Adhikari B, Peto TJ, Promnarate C, Dhorda M, Sirithiranont P, Mukaka M, Peerawaranun P, Day NPJ, Cobelens F, Dondorp AM, Newton PN, White NJ, von Seidlein L, Mayxay M.

Malar J. 2020 Jan 3;19(1):4. doi: 10.1186/s12936-019-3091-5. Erratum in: Malar J. 2020 Jan 21;19(1):32.

7.

Inequity in healthcare needs, health service use and financial burden of medical expenditures in China: results from a consecutive household monitoring study in Jiangsu Province.

Jiang W, Xu X, Tang S, Xu L, Zhang Y, Elbers C, Cobelens F, Yan L.

BMC Health Serv Res. 2019 Dec 16;19(1):966. doi: 10.1186/s12913-019-4796-4.

8.

The Risk of Falsely Declaring Noninferiority of Novel Latent Tuberculosis Treatment in Large Trials.

Abubakar I, Cobelens FGJ, Rangaka MX.

Am J Respir Crit Care Med. 2020 Mar 1;201(5):511-513. doi: 10.1164/rccm.201911-2258ED. No abstract available.

9.

Where is the 'global' in the European Union's Health Research and Innovation Agenda?

Berner-Rodoreda A, Rehfuess EA, Klipstein-Grobusch K, Cobelens F, Raviglione M, Flahaut A, Casamitjana N, Fröschl G, Skordis-Worral J, Abubakar I, Ashrafian H, Agardh A, Visser L, Schultsz C, Plasència A, Jahn A, Norton R, van Leeuwen R, Hagander L, Bärnighausen T.

BMJ Glob Health. 2019 Oct 3;4(5):e001559. doi: 10.1136/bmjgh-2019-001559. eCollection 2019. Review.

10.

Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests.

Nathavitharana RR, Yoon C, Macpherson P, Dowdy DW, Cattamanchi A, Somoskovi A, Broger T, Ottenhoff THM, Arinaminpathy N, Lonnroth K, Reither K, Cobelens F, Gilpin C, Denkinger CM, Schumacher SG.

J Infect Dis. 2019 Oct 8;220(Supplement_3):S116-S125. doi: 10.1093/infdis/jiz243.

PMID:
31593600
11.

Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.

Spruijt I, Tesfay Haile D, Suurmond J, van den Hof S, Koenders M, Kouw P, van Noort N, Toumanian S, Cobelens F, Goosen S, Erkens C.

Eur Respir J. 2019 Nov 28;54(5). pii: 1900861. doi: 10.1183/13993003.00861-2019. Print 2019 Nov.

PMID:
31537698
12.

How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?

Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong BC, Rigouts L.

J Clin Microbiol. 2019 Oct 23;57(11). pii: e00717-19. doi: 10.1128/JCM.00717-19. Print 2019 Nov.

13.

Unmasking the hidden tuberculosis mortality burden in a large post mortem study in Maputo Central Hospital, Mozambique.

Garcia-Basteiro AL, Hurtado JC, Castillo P, Fernandes F, Navarro M, Lovane L, Casas I, Quintó L, Jordao D, Ismail MR, Lorenzoni C, Carrilho C, Sanz A, Rakislova N, Mira A, Alvarez-Martínez MJ, Cossa A, Cobelens F, Mandomando I, Vila J, Bassat Q, Menendez C, Ordi J, Martínez MJ.

Eur Respir J. 2019 Oct 1;54(3). pii: 1900312. doi: 10.1183/13993003.00312-2019. Print 2019 Sep.

14.

Implementation of latent tuberculosis infection screening and treatment among newly arriving immigrants in the Netherlands: A mixed methods pilot evaluation.

Spruijt I, Erkens C, Suurmond J, Huisman E, Koenders M, Kouw P, Toumanian S, Cobelens F, van den Hof S.

PLoS One. 2019 Jul 1;14(7):e0219252. doi: 10.1371/journal.pone.0219252. eCollection 2019.

15.

Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear-Negative Drug-Resistant Tuberculosis, China.

Huang F, van den Hof S, Qu Y, Li Y, Zhang H, Wang L, Sun M, Lu W, Hou S, Zhang T, Huan S, Chin DP, Cobelens F.

Emerg Infect Dis. 2019 Jul;25(7):1289-1296. doi: 10.3201/eid2507.181417.

16.

Detection, survival and infectious potential of Mycobacterium tuberculosis in the environment: a review of the evidence and epidemiological implications.

Martinez L, Verma R, Croda J, Horsburgh CR Jr, Walter KS, Degner N, Middelkoop K, Koch A, Hermans S, Warner DF, Wood R, Cobelens F, Andrews JR.

Eur Respir J. 2019 Jun 27;53(6). pii: 1802302. doi: 10.1183/13993003.02302-2018. Print 2019 Jun. Review.

PMID:
31048345
17.

Horizon Europe: towards a European agenda for global health research and innovation.

Abubakar I, Plasencia A, Bärnighausen T, Froeschl G, Burton M, Cobelens F.

Lancet. 2019 Mar 30;393(10178):1272-1273. doi: 10.1016/S0140-6736(19)30287-9. No abstract available.

PMID:
30938305
18.

Impact of an innovative financing and payment model on tuberculosis patients' financial burden: is tuberculosis care more affordable for the poor?

Jiang WX, Long Q, Lucas H, Dong D, Chen JY, Xiang L, Li Q, Huang F, Wang H, Elbers C, Cobelens F, Tang SL.

Infect Dis Poverty. 2019 Mar 24;8(1):21. doi: 10.1186/s40249-019-0532-x.

19.

Spotting the old foe-revisiting the case definition for TB.

Houben RMGJ, Esmail H, Emery JC, Joslyn LR, McQuaid CF, Menzies NA, Sanz J, Shrestha S, White RG, Yang C, Cobelens F.

Lancet Respir Med. 2019 Mar;7(3):199-201. doi: 10.1016/S2213-2600(19)30038-4. No abstract available.

PMID:
30823971
20.

Active contact tracing beyond the household in multidrug resistant tuberculosis in Vietnam: a cohort study.

Hoang TTT, Nguyen VN, Dinh NS, Thwaites G, Nguyen TA, van Doorn HR, Cobelens F, Wertheim HFL.

BMC Public Health. 2019 Feb 28;19(1):241. doi: 10.1186/s12889-019-6573-z.

21.

The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.

von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, Pongvongsa T, Lwin KM, Keereecharoen L, Kajeechiwa L, Thwin MM, Parker DM, Wiladphaingern J, Nosten S, Proux S, Corbel V, Tuong-Vy N, Phuc-Nhi TL, Son DH, Huong-Thu PN, Tuyen NTK, Tien NT, Dong LT, Hue DV, Quang HH, Nguon C, Davoeung C, Rekol H, Adhikari B, Henriques G, Phongmany P, Suangkanarat P, Jeeyapant A, Vihokhern B, van der Pluijm RW, Lubell Y, White LJ, Aguas R, Promnarate C, Sirithiranont P, Malleret B, Rénia L, Onsjö C, Chan XH, Chalk J, Miotto O, Patumrat K, Chotivanich K, Hanboonkunupakarn B, Jittmala P, Kaehler N, Cheah PY, Pell C, Dhorda M, Imwong M, Snounou G, Mukaka M, Peerawaranun P, Lee SJ, Simpson JA, Pukrittayakamee S, Singhasivanon P, Grobusch MP, Cobelens F, Smithuis F, Newton PN, Thwaites GE, Day NPJ, Mayxay M, Hien TT, Nosten FH, Dondorp AM, White NJ.

PLoS Med. 2019 Feb 15;16(2):e1002745. doi: 10.1371/journal.pmed.1002745. eCollection 2019 Feb.

22.

Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy.

Gil-Santana L, Cruz LAB, Arriaga MB, Miranda PFC, Fukutani KF, Silveira-Mattos PS, Silva EC, Oliveira MG, Mesquita EDD, Rauwerdink A, Cobelens F, Oliveira MM, Kritski A, Andrade BB.

Sci Rep. 2019 Feb 4;9(1):1381. doi: 10.1038/s41598-018-37860-5.

23.

Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis.

Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, Trajman A, Zijenah LS, Mason P, Bandason T, Durovni B, Bara W, Hoelscher M, Clowes P, Mangu C, Chanda D, Pym A, Mwaba P, Cobelens F, Nicol MP, Dheda K, Churchyard G, Fielding K, Metcalfe JZ.

Lancet Glob Health. 2019 Feb;7(2):e191-e199. doi: 10.1016/S2214-109X(18)30458-3. Erratum in: Lancet Glob Health. 2019 Apr;7(4):e419.

24.

Can we predict tuberculosis cure? What tools are available?

Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denkinger CM, Cobelens F.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review.

25.

Results of Early Virologic Monitoring May Facilitate Differentiated Care Monitoring Strategies for Clients on ART, Rakai, Uganda.

Ssempijja V, Chang LW, Nakigozi G, Ndyanabo A, Quinn TC, Cobelens F, Wawer M, Gray R, Serwadda D, Reynolds SJ.

Open Forum Infect Dis. 2018 Oct 9;5(10):ofy212. doi: 10.1093/ofid/ofy212. eCollection 2018 Oct.

26.

An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.

Kik SV, Schumacher S, Cirillo DM, Churchyard G, Boehme C, Goletti D, Rangaka MX, Denkinger CM, Lienhardt C, Gilpin C, Matteelli A, Cobelens F.

Eur Respir J. 2018 Oct 25;52(4). pii: 1800946. doi: 10.1183/13993003.00946-2018. Print 2018 Oct.

PMID:
30139776
27.

What is the true tuberculosis mortality burden? Differences in estimates by the World Health Organization and the Global Burden of Disease study.

García-Basteiro AL, Brew J, Williams B, Borgdorff M, Cobelens F.

Int J Epidemiol. 2018 Oct 1;47(5):1549-1560. doi: 10.1093/ije/dyy144.

PMID:
30010785
28.

Drivers of Seasonal Variation in Tuberculosis Incidence: Insights from a Systematic Review and Mathematical Model.

Tedijanto C, Hermans S, Cobelens F, Wood R, Andrews JR.

Epidemiology. 2018 Nov;29(6):857-866. doi: 10.1097/EDE.0000000000000877.

29.

Correction: Latent tuberculosis infection in foreign-born communities: Import vs. transmission in The Netherlands derived through mathematical modelling.

Korthals Altes H, Kloet S, Cobelens F, Bootsma M.

PLoS One. 2018 May 24;13(5):e0198376. doi: 10.1371/journal.pone.0198376. eCollection 2018.

30.

The convergent epidemiology of tuberculosis and human cytomegalovirus infection.

Cobelens F, Nagelkerke N, Fletcher H.

Version 2. F1000Res. 2018 Mar 6 [revised 2018 Jan 1];7:280. doi: 10.12688/f1000research.14184.2. eCollection 2018.

31.

BCG vaccination protects against infection with Mycobacterium tuberculosis ascertained by tuberculin skin testing.

Pelzer PT, Mutayoba B, Cobelens FGJ.

J Infect. 2018 Oct;77(4):335-340. doi: 10.1016/j.jinf.2018.03.010. Epub 2018 May 18.

PMID:
29778630
32.

Latent tuberculosis infection in foreign-born communities: Import vs. transmission in The Netherlands derived through mathematical modelling.

Korthals Altes H, Kloet S, Cobelens F, Bootsma M.

PLoS One. 2018 Feb 14;13(2):e0192282. doi: 10.1371/journal.pone.0192282. eCollection 2018. Erratum in: PLoS One. 2018 May 24;13(5):e0198376.

33.

IP-10 Kinetics in the First Week of Therapy are Strongly Associated with Bacteriological Confirmation of Tuberculosis Diagnosis in HIV-Infected Patients.

García-Basteiro AL, Mambuque E, den Hertog A, Saavedra B, Cuamba I, Oliveras L, Blanco S, Bulo H, Brew J, Cuevas LE, Cobelens F, Nhabomba A, Anthony R.

Sci Rep. 2017 Oct 30;7(1):14302. doi: 10.1038/s41598-017-13785-3.

34.

Tuberculosis-making predictions, especially about the future.

Mandalakas AM, Cobelens F.

Lancet Infect Dis. 2017 Nov;17(11):1106-1107. doi: 10.1016/S1473-3099(17)30492-9. Epub 2017 Aug 18. No abstract available.

35.

The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa.

Hermans S, Caldwell J, Kaplan R, Cobelens F, Wood R.

Bull World Health Organ. 2017 Aug 1;95(8):554-563. doi: 10.2471/BLT.16.185314. Epub 2017 Apr 28.

36.

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis.

Kapata N, Grobusch MP, Chongwe G, Chanda-Kapata P, Ngosa W, Tembo M, Musonda S, Katemangwe P, Bates M, Mwaba P, Zumla A, Cobelens F.

Infection. 2017 Dec;45(6):831-839. doi: 10.1007/s15010-017-1054-8. Epub 2017 Aug 4.

PMID:
28779436
37.

The Good, the Bad and the Ugly of the Next-Generation Xpert Mtb/Rif® Ultra Test for Tuberculosis Diagnosis.

García-Basteiro AL, Saavedra B, Cobelens F.

Arch Bronconeumol. 2017 Dec;53(12):665-666. doi: 10.1016/j.arbres.2017.05.023. Epub 2017 Jul 10. English, Spanish. No abstract available.

PMID:
28705388
38.

Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.

Boere TM, Visser DH, van Furth AM, Lips P, Cobelens FGJ.

Eur Respir J. 2017 Jun 15;49(6). pii: 1601979. doi: 10.1183/13993003.01979-2016. Print 2017 Jun.

39.

Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda.

Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, de Jong BC, Cobelens FG, van Leth F.

Int J Tuberc Lung Dis. 2017 May 1;21(5):531-536. doi: 10.5588/ijtld.16.0544.

PMID:
28399968
40.

Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation.

Miranda P, Gil-Santana L, Oliveira MG, Mesquita ED, Silva E, Rauwerdink A, Cobelens F, Oliveira MM, Andrade BB, Kritski A.

PLoS One. 2017 Apr 6;12(4):e0175278. doi: 10.1371/journal.pone.0175278. eCollection 2017.

41.

The prevalence of HIV among adults with pulmonary TB at a population level in Zambia.

Chanda-Kapata P, Kapata N, Klinkenberg E, Grobusch MP, Cobelens F.

BMC Infect Dis. 2017 Mar 29;17(1):236. doi: 10.1186/s12879-017-2345-5.

42.

Tuberculosis on the rise in southern Mozambique (1997-2012).

García-Basteiro AL, Miranda Ribeiro R, Brew J, Sacoor C, Valencia S, Bulo H, Cobelens F, Macete E.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601683. doi: 10.1183/13993003.01683-2016. Print 2017 Mar. No abstract available.

43.

Apples, oranges and chest X-rays.

Cobelens F.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):472. doi: 10.5588/ijtld.16.0841. No abstract available.

PMID:
28284266
44.

Tuberculosis drug resistance in Southern Mozambique: results of a population-level survey in the district of Manhiça.

Valencia S, Respeito D, Blanco S, Ribeiro RM, López-Varela E, Sequera VG, Saavedra B, Mambuque E, Morillo MG, Bulo H, Cobelens F, Macete E, Alonso PL, Caminero JA, García-Basteiro AL.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):446-451. doi: 10.5588/ijtld.16.0694.

PMID:
28284261
45.

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.

Kendall EA, Azman AS, Cobelens FG, Dowdy DW.

PLoS One. 2017 Mar 8;12(3):e0172748. doi: 10.1371/journal.pone.0172748. eCollection 2017.

46.

Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.

Cox H, Dickson-Hall L, Ndjeka N, Van't Hoog A, Grant A, Cobelens F, Stevens W, Nicol M.

PLoS Med. 2017 Feb 21;14(2):e1002238. doi: 10.1371/journal.pmed.1002238. eCollection 2017 Feb.

47.

Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.

Xia H, Zheng Y, Zhao B, van den Hof S, Cobelens F, Zhao Y.

PLoS One. 2017 Jan 12;12(1):e0169413. doi: 10.1371/journal.pone.0169413. eCollection 2017.

48.

It takes more than a sensitive test to find more tuberculosis cases.

Trajman A, Cobelens F.

Lancet Infect Dis. 2017 Apr;17(4):357-358. doi: 10.1016/S1473-3099(16)30458-3. Epub 2017 Jan 5. No abstract available.

PMID:
28063794
49.

From latent to patent: rethinking prediction of tuberculosis.

Cobelens F, Kik S, Esmail H, Cirillo DM, Lienhardt C, Matteelli A.

Lancet Respir Med. 2017 Apr;5(4):243-244. doi: 10.1016/S2213-2600(16)30419-2. Epub 2016 Dec 22. No abstract available.

PMID:
28017341
50.

A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Fofana MO, Shrestha S, Knight GM, Cohen T, White RG, Cobelens F, Dowdy DW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00498-16. doi: 10.1128/AAC.00498-16. Print 2017 Mar.

Supplemental Content

Loading ...
Support Center